JULY 1st - SEPTEMBER 30th (Previous year in brackets)
- Net sales amounted to TSEK 198 (TSEK 132).
- Earnings before interest and taxes (EBIT) amounted to MSEK -5,2 (MSEK 6,2).
- Earnings per share after dilution at SEK -0,07 (SEK 0,09).
- Cash flow from operating activities amounted to TSEK -5 114 (TSEK -6 214).
- Liquid assets at the end of the period MSEK 3,7 (MSEK 16,4).
- Equity ratio was 77 % (86 %).
JANUARY 1st-SEPTEMBER 30th (Previous year in brackets)
- Net sales amounted to TSEK 904 (TSEK 472).
- Earnings before interest and taxes (EBIT) amounted to MSEK -16,4 (MSEK 3,98).
- Earnings per share after dilution at SEK -0,23 (SEK 0,06).
- Cash flow from operating activities amounted to MSEK -12,7 (MSEK -3,46).
- Liquid assets at the end of the period MSEK 3,7 (MSEK 16,4).
- Equity ratio was 77 % (86 %).
Summary of events during third quarter
- RLS issues new shares by way of set-off, totaling TSEK 10 000.
- An article regarding ChloraSolv is published in Journal of Wound Care.
Summary of events after third quarteR
- New CEO Björn Larsson starts October 1.
- RLS has raised liquid assets through a new issue in November 2022 (rights issue) of MSEK 29.4.
- The Swedish Medicines Agency has approved RLS' application for pressure ulcers.
- RLS visits the conference Wounds UK in Harrogate, England.
The Interim Report Q3, 2022, is enclosed and is also available here (https://rls.global/financial-information/financial-reports-eng/).
Publication
This information was submitted for publication through the agency of the below contact person,at 08.00 CET on November 24, 2022.